Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gentian Diagnostics AS's enterprise value is kr552.7 Mil.
Gentian Diagnostics AS's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was kr9.4 Mil. Therefore, Gentian Diagnostics AS's EV-to-EBITDA for today is 58.94.
The historical rank and industry rank for Gentian Diagnostics AS's EV-to-EBITDA or its related term are showing as below:
OSL:GENT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -166.36 Med: -40.2 Max: 358.46
Current: 58.95
During the past 13 years, the highest EV-to-EBITDA of Gentian Diagnostics AS was 358.46. The lowest was -166.36. And the median was -40.20.
OSL:GENT's EV-to-EBITDA is ranked worse than 90.86% of 514
companies
in the Medical Devices & Instruments industry
Industry Median: 14.825
vs OSL:GENT: 58.95
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Gentian Diagnostics AS (OSL:GENT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gentian Diagnostics AS's PE Ratio (TTM) for today is calculated as:
Gentian Diagnostics AS's share price for today is kr39.80.
Gentian Diagnostics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:GENT vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's EV-to-EBITDA falls into.
Gentian Diagnostics AS's current Enterprise Value is kr552.7 Mil.
Gentian Diagnostics AS's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr9.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (OSL:GENT) has a EV-to-EBITDA of 58.94 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gentian Diagnostics AS. According to the industry distribution chart, Gentian Diagnostics AS ranks #467 out of 514 companies in the Medical Devices & Instruments industry, placing it in the top 90.9%.
Is Gentian Diagnostics AS's EV-to-EBITDA too high?
Gentian Diagnostics AS's current EV-to-EBITDA is 58.94. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.83. Gentian Diagnostics AS's value of 58.94 is 297.6% above this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #467 out of 514 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Gentian Diagnostics AS has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #467 out of 514 companies for EV-to-EBITDA. This places Gentian Diagnostics AS in the lower half of its industry. The industry median EV-to-EBITDA is 14.83. Gentian Diagnostics AS's value of 58.94 is 297.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.83, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current EV-to-EBITDA of 58.94 is 297.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gentian Diagnostics AS. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current EV-to-EBITDA is 58.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.44, compared to a current price of kr39.80 — trading 33% below its estimated fair value. The current EV-to-EBITDA is 58.94 and 297.6% above the Medical Devices & Instruments industry median of 14.83. Gentian Diagnostics AS's overall GF Score™ is 76/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current EV-to-EBITDA is 58.94 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of kr39.80 is trading 33% below its estimated GF Value™ of kr59.44.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for OSL:GENT:
EV-to-EBITDA: 58.94
GF Value™: kr59.44 vs. price of kr39.80 (33% below fair value)
Industry Position: 297.6% above the Medical Devices & Instruments median (#467 of 514)
No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
76GF Score
Get the complete analysis for OSL:GENT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:GENT has been successfully added to your 
